Island Pharmaceuticals Ltd. confirmed it has submitted its responses to previous guidance provided by the US Food & Drug Administration (FDA) on the clinical development program for Galidesivir. It follows recent confirmation by the FDA that developing a countermeasure for Marburg virus is eligible for the Animal Rule pathway - a significant regulatory derisking event which positions the Company to advance to the next stage of development for the Galidesivir program. Along with confirmation of the Animal Rule pathway, the FDA also provided valuable guidance on Galidesivir's development program to advance approval under the Animal Rule.
The Company was then given the opportunity to submit questions to the FDA by 2 December 2025 (US time), which it has now completed in accordance with the designated time frame. The submission by Island comprises written responses and requests for clarifications where applicable, and marks an important step in ILA's ongoing and comprehensive engagement with the FDA to optimise its development program design in accordance with the highest standards of safety and quality control. A response from the FDA is anticipated by 2 January 2026 (US time).
The Company will incorporate all additional guidance into its NHP study design that will be finalised in close consultation with the FDA. Island is currently advancing agreements with potential facilities to conduct the agreed upon study and continuing US Government engagement initiatives. The Company intends to commence the Marburg study in First Quarter CY26 based on program approval by FDA.
